Citations

Clear

19 citation(s) found for "Kewan, Tariq".

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q
Navarro, Vı́ctor , Haferlach, Claudia, Chan, Onyee , Schulz, Felicitas , Briski, Robert , Al-Ali, Najla, Xicoy, Blanca , Lopez-Cadenas, Felix, Bosch, Francesc, Aguilera, Anna, Meggendorfer, Manja , Eder, Lea Naomi, Jérez, Andrés, Betz, Beate, Kewan, Tariq, Zindel, C., Al‐Kali, Aref , Platzbecker, Uwe, Haase, Detlef Thomas, Zeidan, Amer M., Fenaux, Pierre, Garcia-Manero, Guillermo, Germing, Ulrich, Maciejewski, Jaroslaw P., Haferlach, T, Montoro, Maria Julia , Navarro, Víctor , Chan, Onyee , Kubota, Yasuo , Briski, Robert , Xicoy, Blanca , Romero, Anna Aguilera , Campagna, Alessia , Lanino, Luca , Santini, Valeria , Bernal, Teresa , Such, Esperanza , Platzbecker, Anne Sophie , Gurnari, Carmelo , Zindel, Carla , Kulasekararaj, Austin , Voso, Maria Teresa , Sekeres, Mikkael A , Venugopal, Sangeetha , Al-Kali, Aref , Diez-Campelo, Maria , Wiseman, Daniel H , Della Porta, Matteo Giovanni , Komrokji, Rami S , Solé, Francesc , Palomo, Laura , Valcárcel, David , Acha, Pamela , Haferlach, Claudia , Al‐Ali, Najla, Cadenas, Félix López , Bosch, Francesc, Jerez, Andrés , Wang, Y C , Campagna, Alessia , Lanino, Luca , Santini, Valeria , Gurnari, Carmelo , Kulasekararaj, Austin , Voso, Maria Teresa , Sekeres, Mikkael A. , Varela, Nicolas A Diaz , Platzbecker, Uwe , Haase, Detlef, Zeidan, Amer M. , Fenaux, Pierre , Díez‐Campelo, María , Garcia‐Manero, Guillermo , Wiseman, Daniel H. , Germing, Ulrich , Maciejewski, Jaroslaw P. , Komrokji, Rami S. , Solé, Françesc , Haferlach, Torsten , Valcárcel, David

Mayo Clinic

Blood Advances | July 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020633 | PMID 42466989 Get It

Myelodysplastic syndromes with isolated deletion of chromosome 5q [MDS-del(5q)] constitute a distinct biological entity traditionally associated with favorable outcomes, although up to one quarter of patients progress to acute myeloid leukemia (AML). Existing prognostic models, developed in heterogeneous MDS populations, may not adequately capture risk within this subgroup. We assembled an international cohort of 682 patients with MDS-del(5q) to evaluate the performance of the IPSS-R and IPSS-M, identify prognostic variables, and develop a disease-specific prognostic tool, the IPSS-del(5q). Most patients were classified as lower-risk by IPSS-R (94.4%) and IPSS-M (85.5%), yet both systems showed limited discriminatory ability (C-indices ≈0.5). Independent adverse prognostic factors included age ≥70 years, male sex, anemia (hemoglobin ≤10 g/dL), thrombocytopenia (platelets ≤100×10⁹/L), the presence of one additional chromosomal abnormality, ≥2 gene mutations, SF3B1 mutations, and high-risk TP53 status. Six variables were included in the IPSS-del(5q), stratifying patients into standard-risk (74.3%) and high-risk (25.7%) groups with significantly different LFS (69.2 vs. 32.0 months; p<0.01). Moreover, this model reclassified 19.1% of lower-risk IPSS-R and 14.6% of lower-risk IPSS-M patients into the high-risk IPSS-del(5q) group. However, its discriminative power remained modest, with a C-index of 0.60. Overall, this study provides the most comprehensive prognostic evaluation of MDS-del(5q) to date, demonstrates the limited discriminatory capacity of existing MDS scores in this entity, and underscores the need to develop refined disease-specific prognostic approaches for this MDS subtype.
Real‐world, multi‐omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS)
Sauta, Elisabetta, Lanino, Luca, Bewersdorf, Jan P, Kewan, Tariq, Ali, Najla H. Al, Fenaux, Pierre, Platzbecker, Uwe, Santini, Valeria, Brunner, Andrew M., Kuykendall, Andrew T., Bennett, John M. , Buckstein, Rena, Bejar, Rafael, Carraway, Hetty E., DeZern, Amy E., Hasserjian, R., Loghavi, Sanam, Odenike, Olatoyosi, Padron, Eric , Patnaik, Mrinal M., Stahl, Maximilian, Sekeres, M., Steensma, David P., Savona, Michael R., Taylor, Justin, Xu, Mina L., Sallman, David A., Nimer, Stephen D. , Hourigan, Christopher S., Wei, Andrew H., Riva, Elena , Ventura, Denise, Pinocchio, Nicole, Buizza, Alessandro , Russo, Antonio, D'Amico, Saverio, Delleani, Mattia , Travaglino, Erica , Tentori, Cristina A., Ferrari, Ivan, Crespi, Alessandra, Figini, Giulia , Matteo, Maria Di, Milanesi, Chiara, Castellani, Gastone, Borate, Uma M., Gore, Steven D., Kim, Tae K., Loosdrecht, Arjan A. van de , Daver, N., Wang, Sa A. , Foucar, Kathryn, Iastrebner, Marcelo, Miyazaki, Yasushi, Al‐Kali, Aref, Mittelmann, Moshe, Cluzeau, Thomas , Ades, Lionel, Germing, Ulrich, Garcia‐Manero, Guillermo, Kordasti, Shahram, Haferlach, Torsten, Zeidan, Amer M., consortia, An international study on behalf of GenoMed4all, Synthema, and icMDS, Zeidan, Amer M. , Buizza, Alessandro , Ficara, Francesca , Efficace, Fabio , Diez-Campelo, Maria , Orfao, Alberto , Wang, Sa A , Cluzeau, Thomas , Komrokji, Rami S , Della Porta, Matteo Giovanni , Zeidan, Amer M , Maggioni, Giulia , Todisco, Gabriele , Sauta, Elisabetta , Lanino, Luca , Ball, Somedeb , Bewersdorf, Jan Philipp , Fenaux, Pierre , Platzbecker, Uwe , Santini, Valeria , Xie, Zhuoer , Brunner, Andrew M. , Kuykendall, Andrew , Buckstein, Rena , Bejar, Rafael , Carraway, Hetty E. , Dezern, Amy Elizabeth , Griffiths, Elizabeth A. , Halene, Stephanie , Hasserjian, Robert P. , List, Alan F. , Loghavi, Sanam , Odenike, Olatoyosi , Patnaik, Mrinal M. , Roboz, Gail J. , Sekeres, Mikkael A. , Steensma, David P. , Savona, Michael R. , Sallman, David A. , Hourigan, Christopher S. , Wei, Andrew H. , Campagna, Alessia , Ubezio, Marta , Ventura, Denise , Pinocchio, Nicole , Zampini, Matteo , Russo, Antonio , Pesce, Francesco , D'Amico, Saverio , Asti, Gianluca , Tentori, Cristina Astrid , Ferrari, Ivan , Matteo, Maria Di, Brindisi, Matteo , Manes, Nicla , Crisafulli, Laura , Ficara, Francesca , Castellani, Gastone , Borate, Uma , Efficace, Fabio , Gore, Steven D. , Díez‐Campelo, María , Rozman, Marı́a , Órfão, Alberto , Foucar, Kathryn , Iastrebner, Marcelo , Scheinberg, Phillip , Miyazaki, Yasushi , Madanat, Yazan F. , Al‐Kali, Aref , Mittelman, Moshe , Adès, Lionel , Germing, Ulrich , Garcia‐Manero, Guillermo , Kordasti, Shahram , Haferlach, Torsten , Komrokji, Rami S.

Mayo Clinic

HemaSphere | June 22, 2026 | Volume: 10 | Issue: 6 | Pages: No page available

10.1002/hem3.70406 | PMID 42339339 Get It

Abstract Myelodysplastic syndromes (MDS) are clinically and biologically diverse disorders, emphasizing the need for personalized treatment approaches. The International Working Group for Prognostication of MDS (IWG_PM) recently introduced a molecular classification, referred to as the MDS taxonomy, that categorizes patients into 16 subgroups based on 21 gene mutations, 6 cytogenetic abnormalities, and loss of heterozygosity (LOH) at TP53 and TET2 loci. This study sought to validate and enhance the clinical relevance of the MDS taxonomy by analyzing a large retrospective cohort ( n = 5136) and transcriptomic data from a prospective cohort ( n = 477). The taxonomy successfully identified subgroups with distinct clinical characteristics and disease progression patterns. However, incorporating gene interactions from taxonomy subgroups did not improve the prognostic performance of the Molecular International Prognostic Scoring System (IPSS‐M). We further assessed whether the taxonomy could guide management in patients receiving disease‐modifying therapies. Except for the “ TP53 ‐complex” subgroup, taxonomy classifications were not predictive of hypomethylating agent response or transplant outcomes. Nonetheless, they correlated with overall survival, suggesting that while both IPSS‐M and the taxonomy capture disease biology, other non‐genetic factors may influence treatment response. RNA sequencing confirmed the biological distinctiveness of the taxonomy groups. Transcriptomic profiling of CD34+ bone marrow cells revealed unique, homogeneous gene expression patterns, particularly within the AML‐like, bi TET2 , SF3B1 , and TP53 ‐complex subgroups. Further integration of multi‐omics data may refine MDS classification, improving clinical decision‐making and guiding the development of targeted therapies.
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents
Fathima, Saubia, Wong, Margaret Mei‐Kay, Gonzalez-Lugo, Jesus, Geyer, Susan M. , Alsugair, Ali, Langer, Kimberly J., Lasho, Terra L. , Finke, Christy, Choi, Jun, Abdul‐Hay, Maher, Ho, Gary , Litzow, M. R., Matin, Aasiya , Hefazi, M., Shah, Mithun V., Al-Kali, Aref, Begna, Kebede H. , Gangat, Naseema , Saliba, A., Kewan, Tariq, Bartoo, Gabriel, Kutzke, Jade, McCullough, Kristen, Sullivan, Megan, Reichard, Kaaren K., Olteanu, Horatiu , Kusne, Yael , Palmer, Jeanne, Punwani, Nathan , Riwes, Mary, Krakow, Elizabeth F., Langston, Amelia , Kourelis, Taxiarchis, Foran, James M. , Patnaik, Mrinal M., Beck, David B. , Mangaonkar, Abhishek A. , Krakow, Elizabeth F. , Riwes, Mary , Alsugair, Ali , Lasho, Terra L , Ho, Gary , Durani, Urshila , Hogan, William J , Gangat, Naseema , Saliba, Antoine N , Go, Ronald S , Warrington, Kenneth J , Olteanu, Horatiu , Murthy, Hemant S , Badar, Talha , Kusne, Yael N , Chhabra, Saurabh , Langston, Amelia , Foran, James M , Koster, Matthew J , Beck, David B , Alkhateeb, Hassan B , Fathima, Saubia , Gonzalez‐Lugo, Jesus D. , Geyer, Susan , Sirenko, Maria , Finke, Christy M. , Abdul‐Hay, Maher , Litzow, Mark R. , Durani, Urshila , Hefazi, Mehrdad , Hogan, William J. , Shah, Mithun V., Al‐Kali, Aref , Saliba, Antoine N. , Go, Ronald S. , Bartoo, Gabriel , Kutzke, Jade L. , McCullough, Kristen , Warrington, Kenneth J. , Sullivan, Megan M. , Reichard, Kaaren K. , Murthy, Hemant S. , Badar, Talha , Palmer, Jeanne , Chhabra, Saurabh , McGuirk, Joseph P. , Kourelis, Taxiarchis , Dingli, David , Koster, Matthew J. , Patnaik, Mrinal M. , Alkhateeb, Hassan B. , Mangaonkar, Abhishek A.

Mayo Clinic

American Journal of Hematology | June 9, 2026 | Volume: 101 | Issue: 9 | Pages: 2166-2176

10.1002/ajh.70401 | PMID 42260942 Get It

ABSTRACT Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA ( n = 35) or alloHSCT ( n = 31). Baseline characteristics such as genetics, co‐morbidities, and performance status were balanced between the groups, except older age in the HMA group. Median follow‐up from therapy initiation was 18 months (95% CI: 11–26), and 14 (21%) deaths were reported (alloHSCT n = 3; HMA n = 11). Among all evaluable patients within the alloHSCT cohort, all patients achieved molecular remission, and a substantial proportion of patients discontinued glucocorticoids (58%). In contrast, HMA therapy was associated with lower but meaningful rates of molecular remission (22%) and glucocorticoid discontinuation (6%). In a real‐world setting, HMA therapy was associated with a high discontinuation rate related to toxicity or lack of response. On multivariable analysis adjusted for age and Charlson Comorbidity Index, alloHSCT was associated with improved overall survival (HR = 0.20, 95% CI: 0.05–0.81; p = 0.024). This association remained consistent across multiple ancillary sensitivity analyses, including restriction to transplant‐eligible patients, patients aged ≤ 75 years, 1:1 matching, and propensity score‐based weighted analyses. Although limited by retrospective design, these findings suggest that alloHSCT remains an attractive and potentially curative strategy in selected patients with VEXAS. Prospective validation of these findings is warranted.
Blast Clearance Dynamics and Time to Response Across IDH1‐ and IDH2 ‐Mutated AML
Najeeb, Mohamad Sheikh, Alkabbani, Oudai, He, Rong , Matin, Aasiya , Mangaonkar, A., Patnaik, Mrinal M. , Gangat, Naseema , Litzow, Mark R. , Yi, Cecila Y. Arana, Foran, James M. , Begna, Kebede H. , Al‐Kali, Aref , Mangaonkar, Abishek, Jevremović, Dragan , Greipp, Patricia T. , Hefazi, Mehrdad , Mangaonkar, Abhishek A. , Hogan, William J. , Alkhateeb, Hassan B. , Shah, Meera , Kewan, Tariq Zuheir , Saliba, Antoine N.

Mayo Clinic

eJHaem | December 15, 2025 | Volume: 6 | Issue: 6 | Pages: No page available

10.1002/jha2.70204 | PMID 41404482 Get It

ABSTRACT Background IDH mutations are found in 15%–20% of acute myeloid leukemia (AML). Recent evidence suggests that IDH mutation subtypes may respond differently to intensive chemotherapy. We evaluated blast clearance patterns, remission outcomes, and overall survival (OS) in AML patients with IDH2 R140, IDH2 R172, and IDH1 R132 mutations to assess differences in treatment response. Methods We retrospectively reviewed AML patients diagnosed at Mayo Clinic, Rochester (2016–2023) with NGS data and treated with intensive chemotherapy (7+3 or CPX‐351). Bone marrow blasts were assessed at diagnosis, mid‐induction, and end‐of‐cycle; blast clearance was defined as < 5%. Composite remission (CRc) included CR/CRi per ELN 2022. IDH2 responders were classified as early (after Cycle 1) or late (≥ 2 cycles). Blast reduction was calculated as log 10 (diagnosis blasts/end‐induction blasts) and normalized per day. OS was measured from diagnosis. Results Among 381 patients, 31 had IDH2 mutations (23 R140, 8 R172) and eight had IDH1 R132. Baseline blasts were similar. Mid‐cycle blasts were lower in R140 versus R172 (4% vs. 10%), with higher clearance (68% vs. 38%). End‐induction blasts were lower in R140 versus R172 (2% vs. 4%) with higher clearance (100% vs. 75%). IDH1 and IDH2 showed similar clearance patterns. Log 10 analyses showed deeper and faster blast reduction in R140 versus R172, with comparable kinetics between IDH1 and IDH2 . OS did not differ across subtypes. Early CRc in IDH2 ‐mutated patients was associated with numerically longer OS. Conclusion IDH2 R140 demonstrated faster blast clearance than R172, while remission and survival were similar across IDH subtypes. Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission.
Treatment-specific prognostic performance of ELN 2022, ELN 2024, and beat AML 2024: A real-world AML validation study
Alkabbani, Oudai, He, Rong , Matin, Aasiya , Mangaonkar, Abhishek A. , Gangat, Naseema , Hogan, William H., Patnaik, Mrinal M. , Foran, James M. , Litzow, Mark R. , Begna, Kebede H. , Al‐Kali, Aref , Kewan, Tariq Zuheir , Jevremović, Dragan , Greipp, Patricia T. , Saliba, Antoine N. , Hefazi, Mehrdad , Hogan, William, Alkhateeb, Hassan B. , Yi, Cecilia Arana , Litzow, Mark R. , Shah, Meera

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 996-996

10.1182/blood-2025-996 Get It

Abstract Introduction The European Leukemia Net (ELN) 2022 stratified acute myeloid leukemia (AML) patients (pts) treated with intensive chemotherapy (IC) into three groups based on genetic features. ELN 2024 (Döhner et al, Blood) and Beat AML 2024 (Hoff et al, Blood Advances) proposed revised systems to better capture the impact of genetic features in pts receiving less-intensive therapy (LIT). Real-world validation across treatment settings, including allogeneic hematopoietic stem cell transplantation (allo-HCT), is warranted. Methods We evaluated the performance of ELN 2022, ELN 2024, and Beat AML 2024 among AML pts treated at Mayo Clinic from 2016 to 2025. Only treated pts with available molecular data included. Response was assessed according to the ELN 2022 criteria. Overall survival (OS) was calculated from diagnosis. Multivariable Cox proportional hazard (CPH) models were used to adjust for covariates. Model performances were assessed using Harrell's c-index. Results 426 AML pts (median age 68 years; 60% male) were included; 195 (46%) received IC and 231 (54%) received LIT, while Allo-HCT was performed in 133 (31%) pts. Complex karyotype was present in 126 (30%) and normal cytogenetics in 143 (34%) pts. Molecular mutations included TP53 (20%), TET2 (18%), DNMT3A (16%), SRSF2 (16%), RUNX1 (16%), ASXL1 (16%), and NPM1 (15%). Among evaluable pts (83%), complete remission (CR) after first-line therapy was achieved in 47%. Risk group assignments varied: ELN 2022 vs. ELN 2024 classified pts as favorable (20% vs. 55%), intermediate (20% vs. 24%), and adverse (60% vs. 20%); Beat AML 2024 categorized pts as favorable (41%), intermediate (21%), and adverse (38%). ELN 2024 reclassified 229 (54%) pts of whom 5% upstaged and 49% downstaged, primarily affecting ELN 2022 adverse (67%) and intermediate (46%) groups. Among LIT-treated, CR rates did not differ across groups in any classification. Per ELN 2024, CR was achieved in 43% (favorable), 67% (intermediate), and 29% (adverse) of the LIT-treated pts. However, among IC-treated pts, CR was higher in favorable/intermediate vs. adverse groups across all models (p&lt;0.0001). Allo-HCT was most common in ELN 2024 intermediate (41%) and favorable (32%) vs. adverse (16%) groups. Median OS (months; 95% CI) for the entire cohort was 15.7 (12.5–20.9) with median follow-up time of 49.8 (40.9-55). By ELN 2022, OS of the entire cohort was 49.4 (30.7–NA) for favorable, 50.0 (29.2–NA) for intermediate, and 8.8 (7.7–11.2) for adverse (p&lt;0.0001). Per ELN 2024, OS of the entire cohort was 25.4 (18.5–37.3), 20.3 (13.4–39.8), and 5.7 (3.4–8.2), respectively (p&lt;0.0001). Beat AML 2024 stratified OS of the entire cohort as 42.5 (30.7–NA), 11.4 (9.3–16.7), and 5.6 (3.5–8.0) for favorable, intermediate, and adverse groups (p&lt;0.0001). ELN 2024 stratified the OS of the pts treated with LIT as 15.7 (10.1-24.9), 8.0 (4.9-13.9), and 6.8 (3.4-10.2) for favorable, intermediate and adverse risk groups, (p &lt;0.0001). Among ELN 2022 adverse-risk pts, those reclassified as favorable per ELN 2024 had superior OS (15.0, 9.8–22.7) compared to intermediate (7.8, 5.0–9.3) or adverse (5.4, 3.3–8.0) risk groups, p&lt;0.0001. C-index (95% CI) for OS in the entire cohort was highest for Beat AML 2024 (0.658, 0.629–0.688), followed by ELN 2022 (0.627, 0.599–0.655), and ELN 2024 (0.600, 0.568–0.631). In LIT-treated pts, ELN 2024 (0.597, 0.558–0.637) and Beat AML 2024 (0.586, 0.545–0.627) outperformed ELN 2022 (0.559, 0.521–0.596). Among allo-HCT pts, regardless of treatment type, ELN 2022 (0.610, 0.539–0.681) performed better than ELN 2024 (0.568, 0.487–0.648). In multivariable CPH models adjusted for age, bone marrow blasts, treatment intensity, and complex karyotype, ELN 2022 and ELN 2024 adverse-risk groups had higher hazard of death (HR 2.4, 1.6–3.5 and HR 1.7, 1.1–2.5, respectively, vs. favorable). No significant difference was observed between intermediate and favorable risk for ELN 2022 (HR 1.4, 0.9–2.2) or ELN 2024 (HR 1.4, 0.9–1.9). Allo-HCT was associated with a lower hazard of death (HR 0.4, 0.3–0.5). Conclusions In this real-world AML cohort, ELN 2024 and Beat AML 2024 improved OS prediction in LIT-treated pts compared to ELN 2022. This advantage was not observed in allo-HCT pts. Multivariable analysis confirmed the adverse-risk group as having the worst prognosis across all models. These findings highlight the importance of aligning molecular risk stratification with treatment modalities to enhance prognostication in AML.
TP53 mutational spectrum and fitness landscape in myeloid neoplasia
UNLU, ERSAN, Bahaj, Waled, Ünlü, Serhan , Brady, Zachary, Cheema, Asfand Yar , Hunyadi, Olivia, Zurowski, Charlotte, Marumo, Atsushi , Lakhotiya, Kartik, Sartori, F , Mandala, Aashray, Maciejewski, Jaroslaw, UNLU, ERSAN, Kewan, Tariq Zuheir , Bravo‐Pérez, Carlos , Brady, Zachary, Hunyadi, Olivia, Sartori, Felipe de Almeida, Mandala, Aashray, Orland, Mark D. , Guarnera, Luca , Gurnari, Carmelo , Visconte, Valeria , Durmaz, Arda

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4360-4360

10.1182/blood-2025-4360 Get It

Abstract Myeloid neoplasia encompasses a heterogeneous and complex molecular landscape whereby the distinct combinatorial patterns associated with clinical phenotypes are difficult to delineate. Given that genetic heterogeneity can be a consequence of the topology of the fitness landscape (peaked/non-peaked=high vs low fitness), we investigated co-mutational patterns in TP53 context as an example of hallmark genomic heterogeneity. Indeed, TP53 gene is characterized by hypomorphic/loss-of-function lesions, truncating mutations (frameshifts, stop codons), missense mutations often having a dominant-negative effect and loss of heterozygosity by chromosome 17p deletion driving clonal expansion. Clinical phenotypes of TP53 mutants are also heterogeneous. Here, we stratify TP53 mutations based on our previous published data1 whereby patients with single-hit TP53 and variant allelic frequency (VAF) &gt;50% were classified as obligatory biallelic, patients with VAF between 23-50% as probable biallelic and &lt;23% as probable monoallelic. A threshold of VAF 23% was optimal to separate monoallelic vs biallelic and was based on all-cause mortality. A tree-based model (RandomForestSRC) was used to build a survival model with VAF as a single covariate and minimum node size set to 15 to optimize the cut-off. Using this cut-off, we delineate the epistatic landscape and potential interactions among different TP53 mutational spectra and its fitness. We curated a cohort of 800 patients with TP53 mutations from our institution. In total 36% of the cases carried single hits while 64% had double hits genomic configuration. About 70% of the mutations were missense and were detected at canonical sites (R175H, Y220C, M237I, R273H, R282W, R248Q). We took into consideration 35 features and clustered our cohort of TP53 mutants using factor analysis. When we stratified the cohort based on our predetermined VAF threshold, we found that majority of the variants with high VAF, to be deemed as obligatory biallelic, co-occurred with complex karyotype. These cases were very homogeneous hence had on average a low number of additional variants, likely due to TP53 clones having reduced fitness in the presence of additional mutations. Conversely, patients without complex karyotype were mostly assigned to the monoallelic group due to low to median VAFs. Consequently, these samples had on average a higher number of additional hits, hence a heterogeneous molecular landscape. To substantiate this finding, we noticed that among monoallelic patients two characteristic pairs were observed (TP53-TET2 and TP53-SF3B1) and showed different patterns according to karyotypic associations. Indeed, both pairs in normal karyotype (TP53-TET2, 65%; TP53-SF3B1, 23%) had the highest number of additional mutations on average compared to other monoallelic hits in complex karyotype suggesting that clones resulting by these pairs were advantageous and produced higher fitness driving heterogeneity when together with other mutations. As a preliminary analysis to characterize the fitness landscape of canonical missense TP53 mutations, we investigated whether distinct TP53 mutations conferred differential clonal fitness by implementing a previously published model of stochastic hematopoietic stem cell growth based on the distribution of allelic frequencies across different age groups. Given a fixed stem cell population pool and a constant mutation rate, the distribution of allelic frequencies in the population of corresponding mutations across age can inform the fitness/selection coefficient. The model predicts that high fit mutations will expand more in the population (high VAF) depending on the time the mutation is allowed to expand (age). Based on the literature, we set the stem cell pool to 100,000 and the mutation rate to 1.4E-8.2We limited our analysis to mutations found in at least 10 individual in our cohort and to single hits due to potential epistatic interactions across multiple mutations in the same gene. Given this criterion two mutations R273H and R248Q were analyzed. Interestingly, we observed a 15% increase in fitness gain for R273H compared to R248Q. In summary, mutational heterogeneity and clonal fitness might provide clues to the diversity of TP53 mutational configurations. Our model will be further optimized for the upcoming ASH meeting by incorporating temporal sampling and increasing sample size to define differences in fitness according to mutation site.
Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database
Ali, Najla Al , Stein, Eytan M. , Brunner, Andrew M. , McMahon, Christine M. , Shallis, Rory M. , Hawkins, Hayley, Chandhok, Namrata S. , Logothetis, Constantine , Bidikian, Aram, Getz, Theodore, Harris, Amyah, Amaya, Maria , Ball, Somedeb , Grenet, Justin , Haferlach, Torsten , Maciejewski, Jaroslaw P. , Sallman, David A. , Al-Rabi, Kamal , Halahleh, Khalid , Pleyer, Lisa , Pappa, Vassiliki, Consagra, Angela , Al‐Kali, Aref , Stahl, Max, Bewersdorf, Jan Philipp , Kewan, Tariq Zuheir , Lanino, Luca , Wei, Wei , Dezern, Amy Elizabeth , Sekeres, Mikkael A. , Uy, Geoffrey L. , Urrutia, Samuel , Carraway, Hetty E. , Desai, Pinkal , Griffiths, Elizabeth A. , Zeidner, Joshua F. , Savona, Michael R. , Roboz, Gail J. , Rolles, Benjamin , Wang, Eunice S. , Xie, Zhuoer , Madanat, Yazan F. , Abaza, Yasmin , Campos, Jaclynn, Badar, Talha , Enjeti, Anoop Kumar , Hiwase, Devendra , Díez‐Campelo, María , Valcárcel, David , Haferlach, Claudia , Kotsianidis, Ιoannis , Pappa, Vasiliki , Santini, Valeria , Ogawa, Seishi , Nannya, Yasuhito , Stahl, Max, Porta, Matteo Giovanni Della , Komrokji, Rami S. , Zeidan, Amer M.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 606-606

10.1182/blood-2025-606 Get It

Abstract Introduction: HMA monotherapy (HMAm) continues to be the standard of care for HR-MDS. While the addition of VEN to azacitidine (AZA) improved overall survival (OS) and complete remission (CR) rates among older pts with acute myeloid leukemia (AML) over AZA monotherapy, the recently completed phase III VERONA trial of AZA+/-VEN in HR-MDS failed to show an OS benefit for AZA/VEN over AZA monotherapy. Using the icMDS VALIDATE database, we compared outcomes of pts with HR-MDS treated with HMA or HMA/VEN as frontline therapy. Methods: The icMDS VALIDATE database includes over 4000 adult MDS pts who received HMA-based therapy from 32 international centers in 9 countries. For this analysis, we included pts with HR-MDS defined by International Prognostic Scoring System [IPSS] ≥1.5 or IPSS-revised [IPSS-R] ≥4 (at diagnosis or HMA initiation) and treated with HMAm or HMA/VEN as frontline therapy for HR-MDS. We assessed responses based on IWG 2023 criteria (Zeidan A et al, Blood 2023). Composite complete remission (cCR) was defined as CR+CRbi+CRuni+CRh+CRequivalent. We calculated OS from time of HMA initiation to date of death from any cause. Pts lost to follow-up were censored at the date they were last known to be alive. We used Kaplan-Meier methods to calculate OS and compared OS between different groups using the log-rank test. We used Cox and logistic regression models to adjust for baseline prognostic variables as appropriate. The study was funded by an independent grant from Abbvie. Results: A total of 1907 pts met eligibility and were included (1552 AZA, 221 decitabine, 134 HMA+VEN). 479 pts subsequently underwent allogeneic stem cell transplant (allo-SCT; 430 after HMAm [32.6%]; 49 after HMA/VEN [37.1%]). Our cohort was enriched for pts with adverse disease characteristics including complex karyotype (33.6%) and TP53 mutations (28.7%). Compared to pts treated with HMA/VEN, pts treated with HMAm were more likely to be male (p=0.012), have lower baseline platelet counts (p=0.037), peripheral blood (PB) blasts (p=0.004), or bone marrow blasts (p&lt;0.001), and were less likely to have very high risk IPSS-M (p&lt;0.001), TP53 mutations (p&lt;0.001), or complex karyotype (p=0.020). In unadjusted analyses, the rate of cCR was significantly lower in HMAm treated pts compared to HMA/VEN treated pts (27.7% vs. 48.8%, p&lt;0.001). However, CR rate was not significantly different (11.7% vs. 17.1% for HMAm and HMA/VEN, respectively, p=0.22). After adjusting for age, sex, and IPSS-M, pts treated with HMA/VEN were more likely to achieve cCR compared to HMAm with an odds ratio (OR) of 2.49 (95% CI: 1.56-3.96, p&lt;0.001). When separated by TP53 mutation status, the OR for cCR for HMA/VEN vs HMAm was 4.17 (95%CI: 2.14-8.31; p&lt;0.001) and 1.27 (95%CI: 0.54-2.86; p=0.57) for TP53 wild-type and TP53-mutant pts, respectively. In unadjusted analyses, median OS was 17.4 months for HMAm and 19.6 months for HMA+VEN, and OS did not differ significantly by treatment type (p=0.33). For HMAm treated pts, the OS rates at year 1, 2, 3 were 0.65 (95%CI: 0.63-0.67), 0.38 (95%CI: 0.36-0.40), and 0.27 (95%CI: 0.25-0.29), respectively. For HMA/VEN treated pts, the OS rates at year 1, 2, 3 were 0.64 (95%CI: 0.56-0.73), 0.45 (95%CI: 0.36-0.56), and 0.37 (95%CI: 0.27-0.51), respectively. In a multivariate analysis adjusting for age, sex, PB blast, IPSS-M and allo-SCT as a time-varying covariate, treatment with HMA/VEN vs HMAm did not significantly influence OS (hazard ratio (HR) of OS for HMA/VEN vs HMAm: 0.89, 95%CI: 0.69-1.13, p=0.33). When stratified by TP53 mutation status, HR of HMA/VEN vs. HMAm was favorable for TP53 wild-type (HR: 0.47; 95%CI: 0.29-0.74) but not TP53-mutant pts (HR=0.96; 95%CI: 0.66-1.41). Adjusting for other variables in the model, HR for pts who underwent vs. those who did not undergo allo-SCT were 0.65 (95% CI: 0.49-0.85) and 0.36 (95%CI: 0.24-0.53) in TP53 wild-type and mutant patients, respectively. Conclusion: In this large, international retrospective analysis from the icMDS VALIDATE database, HMA/VEN was associated with higher cCR rates—but not CR rates—compared to HMAm among pts with HR-MDS, though we observed no significant differences in OS. In our analysis, clinical benefit from the addition of VEN was most clear in TP53 wild-type pts, and allo-SCT was associated with improved OS regardless of baseline TP53 status. Our analysis was limited by the relatively small number of HMA/VEN-treated pts and heterogeneous real-world treatment patterns.
Which molecular patterns of high-risk myeloid malignancies are concordantly identified using two machine learning algorithms?
Bahaj, Waled, D’Addona, Matteo , Kiwan, Ahmad , Bat, Taha , Maciejewski, Jaroslaw P. , Kewan, Tariq Zuheir , Durmaz, Arda , Gurnari, Carmelo , Ogbue, Olisaemeka , Awada, Hussein , Pagliuca, Simona , Carraway, Hetty E. , Zeidan, Amer M. , Balasubramanian, Suresh , Bat, Taha , Madanat, Yazan F. , Visconte, Valeria

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3485-3485

10.1182/blood-2025-3485 Get It

Abstract Background: Higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) and secondary acute myeloid leukemia (sAML) share overlapping molecular features but both remain clinically diverse with poor prognosis. Machine learning (ML)-based genomic clustering offers an opportunity to redefine disease subgroups beyond traditional clinical prognostic schemes or pathologic classifications. Prognostic scoring systems emphasize outcomes while pathologic classifications morphology resulting in inclusion of patients (pts) with different genetic background into same outcome or morphologic subgroup. We compared our ML-unsupervised clustering (UC) model named molecular nosology1 with the taxonomy model2 to evaluate differences in cluster architecture and clinical relevance in HR-MDS and sAML. Methods We analyzed HR-MDS (≥10% blasts) and sAML pts with available molecular data at diagnosis from a well-annotated cohort. Our molecular nosology model used UC via a binary latent-factor model to generate molecular clusters (MCs). The taxonomy model assigned pts to predefined genomic classes. We compared MC size, genomic enrichment, and overall survival (OS) across diagnostic categories. Concordance was assessed using Adjusted Rand Index (ARI) and Normalized Mutual Information (NMI). Purity and entropy were calculated to assess how concentrated (purity) or dispersed (entropy) each taxonomy group was across MCs. Results Among 898 pts, 367 (41%) had HR-MDS and 531 (59%) had sAML. Median age was 71 (IQR 65–77) years. Compared to sAML, HR-MDS pts had similar age (71 vs. 72, p=0.556) but higher hemoglobin (9.9 vs. 9.3, p&lt;0.001) and platelet counts (91 vs. 50, p&lt;0.001). Normal karyotype was more common in HR-MDS (55% vs. 42%, p&lt;0.001). TET2 (24%), ASXL1 (24%), RUNX1 (23%), and SRSF2 (22%) were the most frequently mutated genes. Using our nosology model, we identified 14 MCs.1 The most frequent were MC2 (normal karyotype) at 22% and MC13 (TP53-complex) at 17%, followed by MC1 (+8/ASXL1/TET2/RUNX1, 12%), MC6 (SRSF2/RAS-pathway, 9%), and MC9 and MC14 (each 8%). Less common clusters included MC12 (5%) and MC3–MC5 (2–3%). For comparison, the taxonomy model included 18 genomic groups: TP53-complex (20%), mNOS (13%), bi-TET2, IDH-STAG2, and no event (each 10%), CCUS-like, SETBP1/-7, and AML-like (each 6%), SRSF2 (4%), del(5q), BCOR/L1, EZH2-ASXL1, and SF3B1 (each 3%), and five rare subgroups (DDX41, der(1;7), U2AF1157, U2AF134, ZRSR2; all &lt;1%). Our MCs aligned closely with several taxonomy groups: 82% of TP53-complex cases were assigned to MC13, 99% of no event cases mapped to MC2, and 97% of del(5q) cases mapped to MC8. Bi-TET2 cases were distributed across MC6 and MC12 (both TET2-enriched); SETBP1/-7 to MC11; and EZH2-ASXL1 cases to MC1 and MC12. In contrast, mNOS, AML-like, and CCUS-like groups were genomically heterogeneous and spanned multiple MCs. ARI and NMI values were 0.391 and 0.458, indicating moderate concordance. Purity was highest in no event (0.989), del(5q) (0.967), and TP53-complex (0.823), and lowest in IDH-STAG2 (0.247), CCUS-like (0.241), and AML-like (0.347), all with high entropy (&gt;2.5), reflecting genomic diversity not captured by taxonomy groups alone. Median OS for the entire cohort was 17 mo (95%CI: 14–20). HR-MDS pts had longer OS vs. sAML (26 vs. 12 mo, p&lt;0.001). OS did not differ significantly between HR-MDS and sAML within most taxonomy groups or MCs, except for MC3 (NA vs. 11 mo, p=0.014), MC6 (111 vs. 15 mo, p&lt;0.001), and MC9 (18 vs. 9 mo, p=0.027) for the nosology model and SF3B1 (129 vs. 23 mo, p=0.033), del(5q) (33 vs. 6 mo, p=0.022), bi-TET2 (25 vs. 8 mo, p=0.019), mNOS (34 vs. 9 mo, p&lt;0.001) for taxonomy. Conclusions Some molecular taxonomy groups showed strong concordance with our nosology-defined clusters, which served as the gold standard for genomically distinct subsets (e.g., TP53-complex, del(5q), and no event), irrespective of diagnosis or blast percentage which may present the stage of the disease. In contrast, taxonomy-defined categories such as CCUS-like, AML-like, and mNOS were more genetically diverse and less aligned with specific clusters in the nosology model. Median OS within most clusters was not significantly influenced by blast count, underscoring the potential of molecular-driven clustering to reveal underlying disease biology not captured by morphology and to refine classification in MDS/AML and sAML with few exceptions (SF3B1 or biTET2). Ref 1.Kewan, Durmaz et al.Nat Commun 2023 2.Bernard, et al.Blood 2024
Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes
Prince-Eladnani, Raja, Schulz, Felicitas , Briski, Robert , Ali, Najla Al , López, Félix, Meggendorfer, Manja , Eder, Lea Naomi, Jerez, Andrés , Betz, Beate, Castillo, Teresa Bernal Del, Zindel, C., Al‐Kali, Aref , Pollini, Antonella, Diral, Elisa , Memoli, Mara , Haase, Detlef, Fenaux, Pierre , Garcia‐Manero, Guillermo , Germing, Ulrich, Maciejewski, Jaroslaw P. , Haferlach, Torsten , Montoro, Maria Julia , Acha, Pamela , Haferlach, Claudia , Chan, Onyee , Kubota, Yasuo, Xicoy, Blanca , Palomo, Laura , Bosch, Francesc , Wang, Yu‐Hung , Campagna, Alessia , Santini, Valeria , Castillo, Teresa Bernal Del, Such, Esperanza , Platzbecker, Anne Sophie , Kewan, Tariq Zuheir , Gurnari, Carmelo , Zindel, Carla, Kulasekararaj, Austin , Voso, Maria Teresa , Sekeres, Mikkael A. , Varela, Nicolas A Diaz , Platzbecker, Uwe , Zeidan, Amer M. , Díez‐Campelo, María , Wiseman, Daniel H. , Porta, Matteo Giovanni Della , Germing, Ulrich , Komrokji, Rami S. , Solé, Françesc , Valcárcel, David

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2068-2068

10.1182/blood-2025-2068 Get It

Abstract Background & aim: Myelodysplastic syndromes with isolated deletion of chromosome 5q (MDS-del(5q)) are associated with low-risk features and favorable prognosis. In contrast, TP53 multihit alterations, typically reflecting biallelic inactivation, are associated with high-risk features and adverse outcomes across MDS subtypes. Although current classification systems exclude MDS-del(5q) cases with TP53 multihit from low-risk categories, the prognostic significance of these alterations in this specific context remains unclear. Methods: We conducted an international, multicenter, retrospective study comparing MDS-del(5q) per 2017 WHO criteria with TP53 multihit alterations (MDS-del(5q) TP53 multihit) from 21 international institutions, to MDS with low blast counts with TP53 multihit alterations without isolated del(5q) (MDS-LB TP53 multihit) from the public data from the study of Bernard et al., Nat Med 2020. Clinical and biological data were collected at diagnosis. Genetic profiling included G-banding and NGS of myeloid genes. TP53 multihit was defined as &gt;1 TP53 mutation or a single mutation with 17p deletion, copy-neutral loss of heterozygosity (LOH), or variant allele frequency (VAF) ≥50%. Patients were stratified as lower- or higher-risk based on IPSS-R and IPSS-M scores. Lower-risk included those with IPSS-R ≤3.5 points or very-low, low, or moderate-low IPSS-M, while higher-risk included those with IPSS-R &gt;3.5 points or moderate-high, high, or very-high IPSS-M. Clinical, molecular features, overall survival (OS), and AML progression were compared between MDS-del(5q) TP53 multihit and MDS-LB TP53 multihit groups. Finally, outcomes between patients with likely biallelic TP53 multihit status, defined as harboring a single TP53 mutation accompanied by a co-occurring deletion/LOH of 17p or a TP53 VAF ≥50%, versus those considered less likely to be biallelic, thus still classified as multihit, defined as having &gt;1 TP53 mutation but a combined VAF &lt;50%, were compared in both MDS-del(5q) and MDS-LB groups. Statistical analysis was performed using R (version 4.2.2). Results: We included 113 patients with a median follow-up of 81.1 months (95% CI 74.9–NR). A total of 45 (39.8%) were MDS-del(5q) TP53 multihit, and 68 (60.2%) MDS-LB TP53 multihit. Compared to MDS-LB TP53 multihit, patients with MDS-del(5q) TP53 multihit had significantly higher platelet counts (209 ×10⁹/L vs. 77 ×10⁹/L) and were more frequently classified as lower-risk by both IPSS-R (75.4% vs. 9.8%) and IPSS-M (90.2% vs. 24.6%). The median number of mutations per patient, excluding TP53, was 1 in both groups, and only SF3B1 mutations were significantly more frequent in the MDS-del(5q) TP53 multihit group compared to MDS-LB TP53 multihit (20.5% vs. 2.9%; p&lt;0.01). Regarding survival, MDS-del(5q) TP53 multihit patients showed an improved OS compared to MDS-LB TP53 multihit (median OS of 57.0 months (95%CI, 43.0–112.0) vs 14.0 months (95%CI, 8.6–19.0); p&lt;0.01). Moreover, while the risk of progression to AML at 48 months were comparable between groups (34.9% for MDS-del(5q) TP53 multihit and 33.0% for MDS-LB TP53 multihit; p=0.8), a significant difference was observed in the timing of AML progression: median time to AML evolution of 31.7 months (IQR 23.4–55.3) in the MDS-del(5q) TP53 multihit group and 7.2 months (IQR 4.1–12.9) in the MDS-LB TP53 multihit group (p&lt;0.01). Notably, no significant differences in outcomes were found between TP53 multihit and most likely biallelic cases in both MDS-del(5q) and MDS-LB cohorts. The impact of complex karyotype (CK) in MDS-LB TP53 multihit was also explored. MDS-LB TP53 multihitwith CK showed a significantly worse OS compared to MDS-LB TP53 multihitwithout CK (median OS of 10.0 months (95% CI 7.5–17.0) vs 40.0 months (95% CI 14.0–NA); respectively; p&lt;0.001. However, the incidence of AML and median time to AML evolution were comparable between both groups. Finally, OS between MDS-LB TP53 multihit patients without CK and the MDS-del(5q) TP53 multihit cohort was compared. Median OS was significantly shorter in the former group (median of 40 months) compared to the latter (median of 61 months) (p &lt;0.01) Conclusions: These findings underscore that, in contrast to other TP53-multihit MDS subtypes, MDS-del(5q) with TP53 multihit alterations constitute a clinically distinct entity with better outcomes, thereby warranting reconsideration of its place in current classification systems.